Trevi Therapeutics, Inc. (TRVI): Capital Expenditures
$12.0K
Year ended 2025-12-31
$238.0K
Trailing 12 months to 2026-06-30
-57.7%
3-year compound annual growth
-17.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.0K | -65.7% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $35.0K | -74.5% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $137.0K | -13.8% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $159.0K | n/a | 2024-03-20, From 2022-01-01 |
| No annual figure between 2020-12-31 and 2022-12-31. | |||
| 2020-12-31 | $32.0K | +255.6% | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | $9.0K | -94.3% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $158.0K | n/a | 2020-03-16, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $12.0K | -65.7% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $1.74M | +55.5% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $50.0K | -94.5% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Fortress Biotech, Inc. (FBIO) | 2024-12-31 | $0 | -100.0% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $24.0K | -98.8% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $105.0K | +483.3% |
| COMPASS Pathways plc (CMPS) | 2024-12-31 | $0 | -100.0% |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗